Based only on the facts in our directory. The right pick still depends on the job you need done.
Lower starting price
Not comparable
Not comparable: DrugCard does not list a price
Free plan
Tie
Neither has one
Higher rating
DrugCard
4.2 against 4.0
Same job?
Yes
Both are Healthcare AI tools
Side by side
Compared on
DrugCard
Immunai
Our rating
4.2Better
4.0
Starts at
Not listed
Not listed
Free plan
No
No
Category
Healthcare AI
Healthcare AI
Plans
See pricing
See pricing
Key features
AI literature screening across 100+ languages
Coverage of 1,500+ local and international medical journals
Adverse-event signal detection for pharmacovigilance teams
Regulatory intelligence and safety database tooling
Automated global assessment reporting
AMICA-OS platform built on single-cell multi-omic immune system data
Target discovery tools for identifying new drug candidates from immune cell behavior
Preclinical evaluation modeling for testing target hypotheses before trials
Clinical trial optimization using immune-response data
One of the industry's largest clinical immunology datasets, built through 30-plus pharma partnerships
Pros
Local-language coverage addresses a gap most competitors leave open
Founded by someone with direct pharmacovigilance industry experience
Operating in 121+ countries with a substantial processed-article volume
Dataset scale, built through partnerships with Fortune 100 pharma companies, gives its models depth smaller labs can't replicate
Covers the full pipeline from target discovery through clinical trial optimization rather than one narrow step
Named partnerships with AstraZeneca, Boehringer Ingelheim, Pfizer, and Novo Nordisk demonstrate real commercial traction
Cons
No published pricing, so budgeting requires a sales conversation
Narrow focus on pharmacovigilance limits use outside drug safety
Small company relative to larger regulatory-software vendors
No published pricing; every engagement is a custom partnership negotiation
Built exclusively for pharmaceutical R&D, inaccessible to academic labs or individual researchers without a deal
Value depends on data-sharing arrangements with partners, which take time to negotiate and set up
Company
DrugCards, founded 2019
Immunai, founded 2018
Prices come from each vendor's pricing page, last checked 20260730. Check the vendor before you buy.
FAQ
Questions people ask
Is DrugCard better than Immunai?
In our reviews DrugCard scores 4.2 and Immunai scores 4.0. The better pick depends on the job. DrugCard: AI-powered literature-screening platform that automates pharmacovigilance and adverse-event monitoring across languages. Immunai: AI platform mapping the human immune system at single-cell resolution to accelerate drug discovery for pharma partners.
DrugCard
Immunai
